These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 17613342)

  • 41. Systematic investigation of time windows for adverse event data mining for recently approved drugs.
    Hochberg AM; Hauben M; Pearson RK; O'Hara DJ; Reisinger SJ
    J Clin Pharmacol; 2009 Jun; 49(6):626-33. PubMed ID: 19451402
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems.
    Glasser SP; Salas M; Delzell E
    J Clin Pharmacol; 2007 Sep; 47(9):1074-86. PubMed ID: 17766697
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Adverse drug effect reporting].
    Vargas Castrillón E
    An Med Interna; 2002 Jun; 19(6):273-4. PubMed ID: 12152384
    [No Abstract]   [Full Text] [Related]  

  • 44. Effect of computerized provider order entry with clinical decision support on adverse drug events in the long-term care setting.
    Gurwitz JH; Field TS; Rochon P; Judge J; Harrold LR; Bell CM; Lee M; White K; LaPrino J; Erramuspe-Mainard J; DeFlorio M; Gavendo L; Baril JL; Reed G; Bates DW
    J Am Geriatr Soc; 2008 Dec; 56(12):2225-33. PubMed ID: 19093922
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Consensus-based recommendations for standardizing terminology and reporting adverse events for emergency department procedural sedation and analgesia in children.
    Bhatt M; Kennedy RM; Osmond MH; Krauss B; McAllister JD; Ansermino JM; Evered LM; Roback MG;
    Ann Emerg Med; 2009 Apr; 53(4):426-435.e4. PubMed ID: 19026467
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children.
    Mosholder AD; Gelperin K; Hammad TA; Phelan K; Johann-Liang R
    Pediatrics; 2009 Feb; 123(2):611-6. PubMed ID: 19171629
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An assessment of patient and pharmacist knowledge of and attitudes toward reporting adverse drug events due to formulation switching in patients with epilepsy.
    McAuley JW; Chen AY; Elliott JO; Shneker BF
    Epilepsy Behav; 2009 Jan; 14(1):113-7. PubMed ID: 18768168
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Physician's guide to pharmacovigilance: terminology and causality assessment.
    Rehan HS; Chopra D; Kakkar AK
    Eur J Intern Med; 2009 Jan; 20(1):3-8. PubMed ID: 19237084
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Short patent lives jeopardize drug and patient safety.
    Hondeghem LM; De Clerck F; Camm J
    J Cardiovasc Pharmacol; 2007 Oct; 50(4):353-7. PubMed ID: 18049301
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Online reporting of adverse reactions.
    Sibbald B
    CMAJ; 2006 Sep; 175(6):582. PubMed ID: 16966658
    [No Abstract]   [Full Text] [Related]  

  • 51. [Interview -- drug legislation -- reporting unexpected adverse drug reactions].
    Ludwig WD
    Pneumologie; 2009 Sep; 63(9):479-80. PubMed ID: 19764017
    [No Abstract]   [Full Text] [Related]  

  • 52. Inadequate reporting of trials compromises the applicability of systematic reviews.
    Gartlehner G; Thieda P; Hansen RA; Morgan LC; Shumate JA; Nissman DB
    Int J Technol Assess Health Care; 2009 Jul; 25(3):323-30. PubMed ID: 19619351
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacovigilance through consumer feedback (reporting) in the mass treatment of lymphatic filariasis using diethylcarbamazine and albendazole in two districts of Sri Lanka.
    Gunawardena S; Sri Ranganathan S; Fernandopulle R
    Trop Med Int Health; 2008 Sep; 13(9):1153-8. PubMed ID: 18631319
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of an adverse drug reaction electronic reporting system integrated into a hospital information system.
    Ortega A; Aguinagalde A; Lacasa C; Aquerreta I; Fernández-Benítez M; Fernández LM
    Ann Pharmacother; 2008 Oct; 42(10):1491-6. PubMed ID: 18780808
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety reporting in clinical trials.
    Neidig JL; Koletar SL
    JAMA; 2001 Apr; 285(16):2077-8. PubMed ID: 11311088
    [No Abstract]   [Full Text] [Related]  

  • 56. Safety reporting in clinical trials.
    Kohl KS; Bonhoeffer J;
    JAMA; 2001 Apr; 285(16):2076-7; author reply 2077-8. PubMed ID: 11311087
    [No Abstract]   [Full Text] [Related]  

  • 57. Safety reporting in clinical trials.
    Colebunders R; De Roo A; Schrooten W
    JAMA; 2001 Apr; 285(16):2076; author reply 2077-8. PubMed ID: 11311086
    [No Abstract]   [Full Text] [Related]  

  • 58. Safety reporting in clinical trials.
    Calis KA; Daniels CE
    JAMA; 2001 Apr; 285(16):2076; author reply 2077-8. PubMed ID: 11311085
    [No Abstract]   [Full Text] [Related]  

  • 59. [Clinical thinking and decision-making in practice. A patient with persistent fever].
    Diemont WL; van Puijenbroek EP; van Grootheest AC
    Ned Tijdschr Geneeskd; 2000 Sep; 144(38):1853-5. PubMed ID: 11020842
    [No Abstract]   [Full Text] [Related]  

  • 60. Modeling an IT Support for Handling Serious Adverse Events in Clinical Trials.
    Fonck S; Deserno T
    Stud Health Technol Inform; 2017; 245():1262. PubMed ID: 29295347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.